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Objective. To report the mid-term results of 63 patients who received a new commercially-available retrievable vena cava
filter, ALN.
Methods. Between January 2001 and October 2005, 63 patients (mean age 65 15 years) underwent placement of ALN
filters. Filter removal was performed when anti-thrombotic prophylaxis was considered unnecessary or when the patient
could safely resume full anticoagulant therapy.
Results. Thirty-five patients (55%) had ilio-femoral venous thrombosis and 28 patients (45%) had ilio-caval thrombosis.
Overall, 49% had pulmonary embolism. Technical success for filter insertion was 100%, without any complications. None
of the procedures aborted or was converted due to technical difficulties. After a median follow-up of 21-months (range
1e48, median 18), there were no cases of pulmonary embolism or vena cava thrombosis. Two patients died of a cause
unrelated to deep venous thrombosis during the follow-up period, without clinical evidence of pulmonary embolism or
filter-associated complications. No device migration was observed. There were 20 (31.7%) retrieval attempts: in 16 cases
filters were retrieved successfully, but 4 cases were aborted. The mean implantation period of the retrieved filter was 179
days (range 53e370).
Conclusion. Our results confirm the clinical efficacy of the ALN filter for preventing potentially fatal pulmonary embo-
lism whilst implanted and in absence of post-insertion complications, even when left in place indefinitely.
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Venous thromboembolism is a common, lethal disease
that recurs frequently and causes serious long-term
complications.1 Full dose anticoagulation is the gold
standard therapy in patients suffering from venous
thromboembolic disease (VTD). However, for patients
with recurrent disease, with contraindications to anti-
coagulation therapy, or with common femoral vein
thrombosis, pulmonary embolism (PE) may be
prevented by using prophylactic caval filters, either
permanent or temporary.2
With the availability of devices that readily can be
placed percutaneously, vena cava filter has become
the most common treatment alternative for PE
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markedly increased.2e4 Nevertheless, placement of
permanent IVC filters can be associated with a number
of long-term complications. Retrievable filters are
a new generation of IVC filters and represent a very
attractive treatment option; in fact; these filters may
be left in place permanently or they may be safely
retrieved after when they become unnecessary.2
We studied a group of 63 patients who were se-
lected for retrievable filter implantation and reviewed
the techniques, indications, as well as the complica-
tion rates.
Materials and Methods
The ALN filter (ALN Implants Chirurgicaux,
Ghisonaccia-FR) is a stainless steel hydrodynamic re-
trievable IVC filter. It has six short legs that ensure its
adherence to the vena cava walls, and three long legs
that guarantee the correct central positioning along
the main axis of the vena cava. This filter isrved.
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associated with occlusion, because of the small por-
tion of vena cava it occupies and the low amount of
metal used for its manufacture.4e9 Moreover, the ex-
clusion of welding points gives this device an excel-
lent corrosion resistance. The ALN filter can be
placed from the femoral, brachial or jugular vein ap-
proach, but it can be retrieved only via the jugular
vein.
Informed consent was obtained from all the patients.
The interventional team comprised an interventional ra-
diologist and a vascular surgeon. Under local anaesthe-
sia, all patients underwent preliminary imaging of the
venacava.Thenumberand thepositionof the renalveins
were noted to identify themost appropriate site for plac-
ing the filter. Filters were placed via left/right brachial
vein (n¼ 28, 44%), contralateral femoral vein (n¼ 24,
38%), right internal jugular vein (n¼ 11, 18%); in all cases
a7-Frenchcatheterwasused. Inall but 4 cases (neoplastic
‘‘free-floating’’ thrombosis of the renal vein protruding
into the IVC), filters were placed in the infrarenal IVC
and a cavo-gramwas performed at the end of the proce-
dure, in order to check for filter position and tilting.
Filter removal was performed when anti-thrombotic
prophylaxis was considered unnecessary or when the
patient could safely resume full anticoagulant ther-
apy. A preliminary cavo-gram, performed via the fem-
oral approach, assessed filter position and tilt with
respect to the caval axis and thrombi entrapped
within the filter. Filter extraction always was per-
formed via the right internal transjugular approach,
using the 9-French Extraction/Repositioning device
made up of a coaxial, longitudinally movable cram-
pon system mounted distally on a steel preformed
wire. Once the crampon cone was positioned at the
apex of the filter, the sheath was advanced over the fil-
ter retracting the hooks from the cava wall and then
the filter was withdrawn.
Follow-up protocol included clinical evaluation
with duplex-ultrasonography 1, 3, 6 and 12-months,
and yearly thereafter, with thoraco-abdominal com-
puted tomography-angiography and abdominal
X-rays 6-months after filter implantation.
Categorical variables were presented as mean
standard deviation; c2-test or Fischer’s exact test
were adopted when needed. Survival was estimated
using the Kaplan-Meier method.
Results
Between January 2001 and October 2005, 63 consecu-
tive patients underwent placement of ALN filters.
The study included 32 males and 31 females, meanage 65 15 years (range 22e89, median 67). Most of the
patients (91%) were hospitalised; they were referred
from the departments of internal medicine (n¼ 30),
general surgery (n¼ 11), cardiology (n¼ 6), ortho-
paedic surgery (n¼ 4), urology (n¼ 4), obstetrics and
gynaecology (n¼ 3), neurosurgery (n¼ 2), intensive
care (n¼ 2) and medical oncology (n¼ 1). Associated
risk factors for VTD were: cancer (n¼ 23), previous
VTD (n¼ 22), recent major surgery (n¼ 10), recent ma-
jor trauma (n¼ 6) and puerperium (n¼ 2).
The diagnosis of deep venous thrombosis (DVT)
was confirmed by means of colour-coded duplex
ultrasonography and/or computed tomography-
angiography (CT-A) in all patients, while the presence
of PE was confirmed by CT-A and/or lung scan:
thirty-five patients (55%) had ilio-femoral thrombosis,
whereas 28 patients (45%) had ilio-caval thrombosis
documented by duplex and/or CT-A. Overall, 49%
(31/63) had PE diagnosed by CT-A and/or lung
scan [18/35 (51%) of the ilio-femoral group and 13/28
of the ilio-caval group (46.4%)]. Indications for filter
placement were PE prophylaxis (33, 52%), temporary
contraindication to anticoagulant therapy with or
without proven PE (29, 47.5%), and anticoagulant
therapy failure (1, 1.7%). Concomitant anticoagulant
therapy for some period of time while the filter was
in place was administered in 33 patients (52.4%); 20
patients received therapeutic doses of low molecular
weight heparin (LMWH), 9 patients oral anticoagu-
lant therapy, and 4 patients prophylactic doses of
LMWH.
Technical success for filter insertion was 100%,
without any complications; in particular no patient
developed puncture-site haematoma or insertion-site
thrombosis. None of the procedures aborted or was
converted due to technical difficulties.
After a median follow-up of 21-months (range 1e48,
median 18), there were no cases of PE or vena cava
thrombosis. Two patients (3.1%) died of DVT-
unrelated causes [1 mesothelioma, 1 cirrhosis] during
the follow-up period without clinical evidence of PE
or filter-associated complications; autopsy informa-
tion was not available for any of these patients. No
device migration was observed.
In the remaining 61 patients, 28 retrievals of ALN
filters was not attempted for various clinical reasons:
12 cases of patient refusal, in 8 patients the referring
physicians decided against removal because of ongo-
ing contraindications to anticoagulation, 8 because the
patients were in unstable condition. The remaining 11
filters are scheduled to be retrieved in the next few
months.
Twenty (31.7%) retrieval attempts were performed
in 20 patients. The ALN retrieval was attemptedEur J Vasc Endovasc Surg Vol 32, November 2006
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tients. In 16 cases (80%) filters were retrieved success-
fully, and all showed small amounts of organized
thrombus strands on the legs of the filters. Retrievals
required a mean of 12 minutes of fluoroscopy (range
8e21). The mean implantation period of the retrieved
filters was 179 days (range 53e370). Four cases were
aborted: the reason for failure of removal was tilting
with respect to the caval axis of 15  in 3 patients
and tight adherence to the cava walls in 1 patient
(Fig. 1). The mean implantation period of the re-
trieved filters was 152 days (range 64e184).
Among the patients with retrieved filters, none
presented with recurrent DVT or PE.
Of the 41 patients (65%) with filters remaining in
place, 3 (7.3%) were lost to follow-up. Overall, among
patients available for follow-up, none reported recur-
rent DVT, PE, or filter-related IVC thrombosis. No fil-
ter migration was observed. During follow-up, none
of the patients required reinsertion of a permanent
filter after ALN retrieval.
At 1 month and 12-months follow-up, Kaplan-
Meier life-time analysis estimated a survival rate of
98% and 96%, respectively.
Discussion
Vena cava filters have been available widely to pre-
vent life-threatening PE since the early seven-
ties.3,4,10,11 The purpose of the modern retrievable
filter is to avoid long-term device-related complica-
tions described with first-generation permanent filter,
especially in patients who might benefit from PE pre-
vention over a short period of time.8e16 The ALN filter
is a stainless steel hydrodynamic retrievable IVCEur J Vasc Endovasc Surg Vol 32, November 2006filter; few trials have recently investigated the efficacy
and safety retrieval of the ALN device.5,6 Our study
confirmed the excellent adherence to the vena cava
walls, and the low thrombogenicity with minimal oc-
clusion of this device. Although IVC thrombosis has
been reported up to 9.3% with first-generation perma-
nent devices, we did not encounter any incidence of
this complication.5,14 Although the reported incidence
of filter movement toward the heart, including spon-
taneous intra-cardiac migration, has been shown to
vary between 1% and 13%, we observed no short or
long-term migration, even in the 6 cases where large
thrombi were trapped within the basket of the filter.
We also observed a low rate of filter tilting (3.4%),
and there were two episodes of asymptomatic filter
legs trans-caval migration during retrieval attempts.
Previous published data showed an acceptable rate
of successful retrieval after medium to long-term
implantation periods.5,6 Our experience compares
favourably, we retrieved quite a large number of de-
vices. In particular, the results of our study add useful
information on the use of ALN filters owing to a lon-
ger follow-up than previously reported and a longer
average period to retrieval (179 days). Interestingly,
in our experience, time from the placement procedure
did not appear to influence the retrieval procedure
and modification of the filter position (e.g. tilting,
trans-caval migration of the filter legs) was the only
event that prevented filter retrieval.6
Our experience supports the efficacy of retrievable
ALN filters in patients at high risk of PE, particularly
those in whom the use of anti-thrombotic therapy is
contraindicated. In our series we did not observe re-
current or fatal PE during the time the filter was in
place. Moreover, the thrombus capture rate was
higher than reported in previous data (12e18%): allFig. 1. Cavogram control (B) in a patient without recurrent DVT and EP in which spiral-CT follow-up scan detected two
major complications: tilting and partial transmigration (A).
599Results of ALN IVC Filterretrieved filters showed small strands of organized
thrombus on the legs of the filters and no symptom-
atic PE appeared during and immediately after the re-
moval procedure despite the trapped emboli within
the filter, which were detected in up to 30% patients.
Conclusion
Our results confirm the clinical efficacy of the ALN
filter either in preventing potentially fatal PE during
implantation times.
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